Protection of Mice Against Pandemic H1N1 Influenza Virus Challenge After Immunization with Baculovirus-Expressed Stabilizing Peptide Fusion Hemagglutinin Protein
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Current influenza vaccines are produced in embryonated chicken eggs. However, egg-based vaccines have various problems. To address these problems, recombinant protein vaccines have been developed as new vaccine candidates. Unfortunately, recombinant proteins frequently encounter aggregation and low stability during their biogenesis. It has been previously demonstrated that recombinantly expressed proteins can be greatly stabilized with high solubility by fusing stabilizing peptide (SP) derived from the C-terminal acidic tail of human synuclein (ATS). To investigate whether SP fusion proteins can induce protective immunity in mice, we produced influenza HA and SP fusion protein using a baculovirus expression system. In in vitro tests, SP-fused recombinant HA1 (SP-rHA1) was shown to be more stable than recombinant HA1 (rHA1). Mice were immunized intramuscularly with baculovirus-expressed rHA1 protein or SP-rHA1 protein (2 μg/mouse) formulated with aluminum hydroxide. Antibody responses were determined by ELISA and hemagglutination inhibition assay. We observed that SP-rHA1 immunization elicited HA-specific antibody responses that were comparable to rHA1 immunization. These results indicate that fusion of SP to rHA1 does not negatively affect the immunogenicity of the vaccine candidate. Therefore, it is possible to apply SP fusion technology to develop stable recombinant protein vaccines with high solubility.
Abstract
Current influenza vaccines are produced in embryonated chicken eggs. However, egg-based vaccines have various problems. To address these problems, recombinant protein vaccines have been developed as new vaccine candidates. Unfortunately, recombinant proteins frequently encounter aggregation and low stability during their biogenesis. It has been previously demonstrated that recombinantly expressed proteins can be greatly stabilized with high solubility by fusing stabilizing peptide (SP) derived from the C-terminal acidic tail of human synuclein (ATS). To investigate whether SP fusion proteins can induce protective immunity in mice, we produced influenza HA and SP fusion protein using a baculovirus expression system. In in vitro tests, SP-fused recombinant HA1 (SP-rHA1) was shown to be more stable than recombinant HA1 (rHA1). Mice were immunized intramuscularly with baculovirus-expressed rHA1 protein or SP-rHA1 protein (2 μg/mouse) formulated with aluminum hydroxide. Antibody responses were determined by ELISA and hemagglutination inhibition assay. We observed that SP-rHA1 immunization elicited HA-specific antibody responses that were comparable to rHA1 immunization. These results indicate that fusion of SP to rHA1 does not negatively affect the immunogenicity of the vaccine candidate. Therefore, it is possible to apply SP fusion technology to develop stable recombinant protein vaccines with high solubility.
참고문헌 (22)
- Altmann F, "Insect cells as hosts for the expression of recombinant glycoproteins", Glycoconj. J, 16, pp.109~123 (1999)
- Braun A, "Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha)in normal and transgenic mice", Pharm. Res, 14, pp.1472~1478 (1997)
- Chua JV, "Bench-to-bedside review: vaccine protection strategies during pandemic flu outbreaks", Crit. Care, 14, pp.218~ (2010)
- Clayton DF, "The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease", Trends Neurosci, 21, pp.249~254 (1998)
- Collin N, "Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza", Vaccine, 27, pp.5184~5186 (2009)
- Jeong KJ, "High-level production of human leptin by fed-batch cultivation of recombinant Escherichia coli and its purification", Appl. Environ. Microbiol, 65, pp.3027~3032 (1999)
- Kim TD, "Structural and functional implications of C-terminal regions of alpha-synuclein", Biochemistry, 41, pp.13782~13790 (2002)
- Kim YM, "Expression of human interferon alpha-1 with enhanced stability via the tagging system of a stabilizing peptide", Protein Expr. Purif, 63, pp.140~146 (2009)
- Kumru OS, "Vaccine instability in the cold chain:mechanisms, analysis and formulation strategies", Biologicals, 42, pp.237~259 (2014)
- Lee EN, "Stabilizing peptide fusion for solving the stability and solubility problems of therapeutic proteins", Pharm. Res, 22, pp.1735~1746 (2005)
- Palese P., "Influenza: old and new threats", Nat. Med, 10, pp.S82~S87 (2004)
- Park SM, "Effects of novel peptides derived from the acidic tail of synuclein(ATS)on the aggregation and stability of fusion proteins. Protein Eng. Des. Sel. 17 : 251-260", Protein Eng. Des. Sel, 17, pp.251~260 (2004)
- Park SM, "Stress-induced aggregation profiles of GST-alphasynuclein fusion proteins: role of the C-terminal acidic tail of alpha-synuclein in protein thermosolubility and stability", Biochemistry, 41, pp.4137~4146 (2002)
- Park SM, "Distinct roles of the N-terminal-binding domain and the Cterminal-solubilizing domain of alpha-synuclein, a molecular chaperone", J. Biol. Chem, 277, pp.28512~28520 (2002)
- Petrovsky N., "Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity", Vaccine, 24(Suppl 2), pp.S2-26~S2-29 (2006)
- Ratner RE, "Persistent cutaneous insulin allergy resulting from high-molecularweight insulin aggregates", Diabetes, 39, pp.728~733 (1990)
- Reperant LA, "Advances in influenza vaccination", F1000Prime Rep, 6, pp.47~ (2014)
- Samant Y, "Evaluation of the cold-chain for oral polio vaccine in a rural district of India", Public Health Rep, 122, pp.112~121 (2007)
- Treanor JJ, "Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults", J. Infect. Dis, 173, pp.1467~1470 (1996)
- Treanor JJ, "Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults", J. Infect. Dis, 193, pp.1223~1228 (2006)
- Treanor JJ, "Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial", JAMA, 297, pp.1577~1582 (2007)
- Volkin DB, "Analysis of vaccine stability", Dev. Biol. Stand, 87, pp.135~142 (1996)